Source: Natesto
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Acerus Pharmaceuticals Corporation (ASP) signs an agreement with Verity Pharmaceuticals for the exclusive rights to promote Natesto in Puerto Rico
  • Natesto is a prescription medicine that contains testosterone and is used to treat adult males who have low or no testosterone
  • Verity Pharma will promote Natesto across the island of Puerto Rico to leverage its existing commercial footprint and health care network
  • Acerus will maintain control of distribution, market access, and regulatory activities
  • Acerus Pharmaceuticals Corporation (ASP) is up 14.29 per cent and is trading at $0.04 per share as of 2:58 p.m. EST

Acerus Pharmaceuticals Corporation (ASP) signs an agreement with Verity Pharmaceuticals for the exclusive rights to promote Natesto in Puerto Rico.

Natesto is a prescription medicine that contains testosterone and is used to treat adult males who have low or no testosterone.

Verity Pharma will promote Natesto across the island of Puerto Rico to leverage its existing commercial footprint and health care network.

Acerus will maintain control of distribution, market access, and regulatory activities.

Edward Gudaitis, President and CEO of Acerus, commented,

“Verity Pharma’s established and significant salesforce and healthcare network in Puerto Rico will be the catalyst to expand patient access to Natesto.”

Howard Glase, CEO of Verity Pharma, said Natesto offers ‘significant value’ to patients suffering from hypogonadism.

Verity Pharma is a privately-owned pharmaceutical company with offices in Canada, the United States, and Ireland.

The company specializes in providing innovative, market-leading pharmaceutical products to patients across North America.

Acerus is a Canadian-based specialty pharmaceutical company with a primary focus in the field of men’s health.

The company commercializes its products via its own salesforce in the U.S., Canada, and through a global network of licensed distributors in other territories.

Acerus Pharmaceuticals Corporation (ASP) is up 14.29 per cent and is trading at $0.04 per share as of 2:58 p.m. EST.

More From The Market Herald

" LevelJump Healthcare (TSXV:JUMP) announces $2.5M private placement

LevelJump Healthcare (JUMP) will be conducting a non-brokered private placement financing for gross proceeds of up to $2,500,000.

" Leveljump Healthcare (TSXV:JUMP) provides corporate update

Leveljump Healthcare (JUMP) has agreed to acquire an additional minority interest in Real Time Medical (RTM), Shaw Lens, and Shaw Vision.

" PharmaDrug (CSE:PHRX) engages Octagon Media for an investor marketing campaign

PharmaDrug Inc. (PHRX) has engaged Octagon Media Corp to assist in a digital media advertising campaign coupled with an investor marketing program.

" Bloom Health Partners Inc. (CSE:BLMH) receives DTC eligibility

Common shares of Bloom Health Partners (BLMH) are now eligible for electronic clearing and settlement through the Depository Trust Company.